23andMe receives FDA clearance for genetic test for prostate cancer marker January 18, 2022 Consumer genetics company 23andMe scored FDA 510(k) clearance for a test to detect a hereditary marker for prostate cancer.The risk report provides information on whether users have the G84E mutation in the HOXB13 gene, which studies have shown can increase a person’s risk of developing prostate cancer. Continue reading this article here.Source: Emily Olsen Prostate Cancer News
Consumer genetics company 23andMe scored FDA 510(k) clearance for a test to detect a hereditary marker for prostate cancer.The risk report provides information on whether users have the G84E mutation in the HOXB13 gene, which studies have shown can increase a person’s risk of developing prostate cancer. Continue reading this article here.Source: Emily Olsen
Complete the Survey
